Purdue OxyContin patent ruling
A New York district court judge rules Jan. 7 that Purdue did not commit inequitable conduct in prosecuting its OxyContin patents before the U.S. Patent and Trademark Office. The court had ruled in 2004 that the patents were invalid and unenforceable due to inequitable conduct in Purdue's infringement suit against Endo. In 2006 the U.S Court of Appeals for the Federal Circuit vacated the district court's finding that the patents on the pain medication were invalid and sent the case back to district court...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.